Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP. Type ...

If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

The top 10 holdings account for about 56.78% of total assets under management. VUG seeks to match the performance of the CRSP U.S. Large Cap Growth Index before fees and expenses. The CRSP US Large ...

The Vanguard Small-Cap Value ETF (VBR) was launched on 01/26/2004, and is a passively managed exchange traded fund designed to offer broad exposure to the Small Cap Value segment of the US equity ...

Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investor ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: ...